%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Gazanion, Elodie
%A Garcia, Deborah
%A Silvestre, R.
%A Gérard, C.
%A Guichou, J. F.
%A Labesse, G.
%A Seveno, Martial
%A Cordeiro-Da-Silva, A.
%A Ouaissi, A.
%A Sereno, Denis
%A Vergnes, Baptiste
%T The Leishmania nicotinamidase is essential for NAD(+) production and parasite proliferation
%D 2011
%L fdi:010053856
%G ENG
%J Molecular Microbiology
%@ 0950-382X
%M ISI:000295226700004
%N 1
%P 21-38
%R 10.1111/j.1365-2958.2011.07799.x
%U https://www.documentation.ird.fr/hor/fdi:010053856
%> https://www.documentation.ird.fr/intranet/publi/2011/10/010053856.pdf
%V 82
%W Horizon (IRD)
%X NAD(+) is a central cofactor that plays important roles in cellular metabolism and energy production in all living cells. Genomics-based reconstruction of NAD(+) metabolism revealed that Leishmania protozoan parasites are NAD(+) auxotrophs. Consequently, these parasites require assimilating NAD(+) precursors (nicotinamide, nicotinic acid, nicotinamide riboside) from their host environment to synthesize NAD(+) by a salvage pathway. Nicotinamidase is a key enzyme of this salvage pathway that catalyses conversion of nicotinamide (NAm) to nicotinic acid (Na), and that is absent in higher eukaryotes. We present here the biochemical and functional characterizations of the Leishmania infantum nicotinamidase (LiPNC1). Generation of Lipnc1 null mutants leads to a decrease in NAD(+) content, associated with a metabolic shutdown-like phenotype with an extensive lag phase of growth. Both phenotypes could be rescued by an add-back construct or by addition of exogenous Na. In addition, Lipnc1 null mutants were unable to establish a sustained infection in a murine experimental model. Altogether, these results illustrate that NAD(+) homeostasis is a fundamental component of Leishmania biology and virulence, and that NAm constitutes its main NAD(+) source in the mammalian host. The crystal structure of LiPNC1 we solved allows now the design of rational inhibitors against this new promising therapeutic target.
%$ 052